Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Measuring viability selection from prospective cohort mortality studies: A case study in maritime pine.

Robledo-Arnuncio JJ, Unger GM.

Evol Appl. 2019 Mar 18;12(5):863-877. doi: 10.1111/eva.12729. eCollection 2019 Jun.


Evaluation of protein kinase CK2 as a therapeutic target for squamous cell carcinoma of cats.

Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K.

Am J Vet Res. 2017 Aug;78(8):946-953. doi: 10.2460/ajvr.78.8.946.


Therapeutic Targeting of Protein Kinase CK2 Gene Expression in Feline Oral Squamous Cell Carcinoma: A Naturally Occurring Large-Animal Model of Head and Neck Cancer.

Cannon CM, Trembley JH, Kren BT, Unger GM, O'Sullivan MG, Cornax I, Modiano JF, Ahmed K.

Hum Gene Ther Clin Dev. 2017 Jun;28(2):80-86. doi: 10.1089/humc.2017.008. Epub 2017 Mar 23.


CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer.

Trembley JH, Kren BT, Abedin MJ, Vogel RI, Cannon CM, Unger GM, Ahmed K.

Pharmaceuticals (Basel). 2017 Feb 21;10(1). pii: E25. doi: 10.3390/ph10010025. Review.


CK2 targeted RNAi therapeutic delivered via malignant cell-directed tenfibgen nanocapsule: dose and molecular mechanisms of response in xenograft prostate tumors.

Ahmed K, Kren BT, Abedin MJ, Vogel RI, Shaughnessy DP, Nacusi L, Korman VL, Li Y, Dehm SM, Zimmerman CL, Niehans GA, Unger GM, Trembley JH.

Oncotarget. 2016 Sep 20;7(38):61789-61805. doi: 10.18632/oncotarget.11442.


Assessing early fitness consequences of exotic gene flow in the wild: a field study with Iberian pine relicts.

Unger GM, Heuertz M, Vendramin GG, Robledo-Arnuncio JJ.

Evol Appl. 2016 Jan 9;9(2):367-80. doi: 10.1111/eva.12333. eCollection 2016 Feb.


Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0. Epub 2015 Feb 11.


Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice.

Trembley JH, Unger GM, Korman VL, Abedin MJ, Nacusi LP, Vogel RI, Slaton JW, Kren BT, Ahmed K.

PLoS One. 2014 Oct 15;9(10):e109970. doi: 10.1371/journal.pone.0109970. eCollection 2014.


Estimating exotic gene flow into native pine stands: zygotic vs. gametic components.

Unger GM, Vendramin GG, Robledo-Arnuncio JJ.

Mol Ecol. 2014 Nov;23(22):5435-47. doi: 10.1111/mec.12946. Epub 2014 Oct 21.


Mechanism and efficacy of sub-50-nm tenfibgen nanocapsules for cancer cell-directed delivery of anti-CK2 RNAi to primary and metastatic squamous cell carcinoma.

Unger GM, Kren BT, Korman VL, Kimbrough TG, Vogel RI, Ondrey FG, Trembley JH, Ahmed K.

Mol Cancer Ther. 2014 Aug;13(8):2018-29. doi: 10.1158/1535-7163.MCT-14-0166. Epub 2014 May 27.


Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Trembley JH, Unger GM, Gomez OC, Abedin J, Korman VL, Vogel RI, Niehans G, Kren BT, Ahmed K.

Mol Cell Pharmacol. 2014;6(2):15-25.


Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Trembley JH, Unger GM, Korman VL, Tobolt DK, Kazimierczuk Z, Pinna LA, Kren BT, Ahmed K.

Cancer Lett. 2012 Feb 1;315(1):48-58. doi: 10.1016/j.canlet.2011.10.007. Epub 2011 Oct 12.


Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice.

Trembley JH, Unger GM, Tobolt DK, Korman VL, Wang G, Ahmad KA, Slaton JW, Kren BT, Ahmed K.

Mol Cell Biochem. 2011 Oct;356(1-2):21-35. doi: 10.1007/s11010-011-0943-x. Epub 2011 Jul 15.


Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.

Kren BT, Unger GM, Sjeklocha L, Trossen AA, Korman V, Diethelm-Okita BM, Reding MT, Steer CJ.

J Clin Invest. 2009 Jul;119(7):2086-99. doi: 10.1172/JCI34332. Epub 2009 Jun 8.


Improving surgical wound healing with basic fibroblast growth factor after radiation.

Hom DB, Unger GM, Pernell KJ, Manivel JC.

Laryngoscope. 2005 Mar;115(3):412-22.


Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model.

Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K.

Mol Cancer Res. 2004 Dec;2(12):712-21.


Protein kinase CK2 as regulator of cell survival: implications for cancer therapy.

Unger GM, Davis AT, Slaton JW, Ahmed K.

Curr Cancer Drug Targets. 2004 Feb;4(1):77-84. Review.


Supplemental Content

Loading ...
Support Center